<DOC>
	<DOCNO>NCT00922779</DOCNO>
	<brief_summary>This single arm study evaluate safety tolerability ribavirin combination PEGASYS patient chronic hepatitis C. Patients receive ribavirin 800mg , 1000-1200mg po daily , accord HCV genotype body weight ( &lt; &gt; 75kg ) combination PEGASYS 180micrograms sc weekly . The anticipated time study treatment 3-12 month , target sample size &gt; 500 individual .</brief_summary>
	<brief_title>A Study Ribavirin Combination With PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; serological evidence chronic hepatitis C ; detectable serum HCVRNA ; liver biopsy finding consistent diagnosis chronic hepatitis C. history evidence medical condition associate chronic liver disease HCV ; coinfection active hepatitis A B ; hepatocellular carcinoma ; patient severe cardiovascular disease whose condition may worsen due acute anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>